Fig 2: DIP2B expression and prognosis analysis in subtypes of BRCA. A-E The expression of DIP2B in subtypes of BRCA. F-J KM plot showing that the expression of DIP2B predicted worse OS in Her-2 + BRCA. Hexp: high expression; Lexp: low expression. ns = not significant (P > 0.05); *P < 0.05; **P < 0.01; ***P < 0.001

Fig 3: Effect of DIP2B siRNA transfection on the migration capability of breast cancer cell lines. A Representative wound-healing images at 0 and 24 h (magnification: × 100) in four breast cancer cell lines. The experiment was repeated three times independently. The scratch width had decreased significantly in the blank control and mock cultures after 24 h, whereas there was still a wider gap in the siRNA-DIP2B cells. B The percentages of wound closure were calculated. *P < 0.05 vs. blank control group

Fig 4: The correlation of DIP2B expression with major histocompatibility complex (MHC)-related genes (A) and chemokine-related genes (B) across cancers. *P < 0.05; **P < 0.01; ***P < 0.001

Fig 5: Correlation analysis of DIP2B expression and immune infiltration and the expression of key immune regulatory genes in subtypes of BRCA. A The relationship between DIP2B expression and immune score. B The relationship between DIP2B expression and immune cell infiltration. The correlations among DIP2B and major histocompatibility complex (MHC)-related genes (C) and chemokine-related genes (D). *P < 0.05; **P < 0.01; ***P < 0.001